Based on the mechanisms and functions of the RAF/MEK/ERK signaling pathway, small molecular inhibitors targeting the signaling pathway have demonstrated excellent treatment effects in cancer patients (Fig. 3) [260]. Here, MAPK1 is linked to cancer.